How many boxes of Canafenib/Encofenib (Betavit) are usually required for one course of treatment?
Canafenib (Encorafenib) is an oral BRAF inhibitor, mainly used to treat BRAF V600 mutation-positive advanced or metastatic melanoma, as well as some patients with colorectal cancer. By selectively inhibiting the abnormally activated BRAF kinase and blocking the MAPK signaling pathway, it inhibits tumor cell proliferation and promotes apoptosis. It is often used in combination with MEK inhibitors (such as Binimetinib) to delay the development of drug resistance and improve treatment efficacy.
According to clinical guidelines, the standard adult dose is 450 mg daily, which can be taken as a single dose or divided into two doses. Since only 75mg capsules are available on the market, patients need to take 6 capsules of 75mg capsules daily to achieve the recommended dose. It is recommended to swallow the tablet whole, preferably with meals or at a fixed time, to maintain stable blood concentration and reduce gastrointestinal discomfort.

A course of treatment is usually calculated as a cycle of 28 days. According to the daily dosage of 6capsules of 75mg capsules, a course of treatment requires a total of 168 capsules. Since each box of medicine usually contains 30 capsules, one course of treatment requires approximately 6boxes of 75mg capsules. If a patient is taking a MEK inhibitor concomitantly, the doctor may adjust the dose based on tolerance, which affects the number of capsules needed.
During the course of treatment, patients should strictly follow the doctor's instructions and should not increase or decrease the dosage or stop the medication on their own. If serious side effects occur, such as rash, fever, abnormal liver function, or changes in heart rhythm, your doctor may temporarily stop the medication or adjust the dose. When purchasing and storing drugs, patients should calculate the number of capsules required in advance, store the drugs properly, and avoid moisture, high temperature or direct sunlight to ensure efficacy and medication safety.
Reference materials:https://www.drugs.com/
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)